Therapeutic neuroscience

Nociplastic pain, the third kind of pain.

For a long time clinicians sorted pain into two boxes. Nociceptive pain comes from injured or inflamed tissue, like a sprained ankle or an arthritic knee. Neuropathic pain comes from damage to the nerves themselves. But many people with chronic pain fit neither box: widespread or intense pain, unremarkable scans, and treatments aimed at tissues or nerves that helped little. In 2021 the pain research community gave that group a name.

Reviewed by The Karuna Labs clinical teamUpdated

What is nociplastic pain?

Nociplastic pain is the IASP's name for pain that arises from altered pain processing in the nervous system without clear tissue damage or nerve injury. Described as a mechanistically distinct third category in a 2021 Lancet review, it is often widespread, more intense than any visible problem explains, and responds less well to treatments aimed at tissues, such as anti-inflammatories, injections or surgery.

It is real pain produced by a real nervous system. The label describes what is driving it, and it points treatment toward the nervous system rather than toward a structural cause that may not exist.

At a glance

Article analysed
Fitzcharles, Cohen, Clauw and colleagues, The Lancet, May 2021: the first major review of nociplastic pain as a category
Definition
Pain from altered nociception without clear evidence of tissue damage activating nociceptors, or of disease or lesion of the somatosensory system
Thought to involve
Augmented pain and sensory processing in the central nervous system, and altered pain modulation
Typical picture
Pain in several body regions, more intense than expected, with fatigue, poor sleep, memory difficulty and mood changes
Examples
Fibromyalgia and tension-type headache on their own; mixed with other mechanisms in much chronic low back pain
Clinical criteria
Kosek et al., Pain 2021: duration and distribution, no sufficient nociceptive or neuropathic explanation, hypersensitivity, associated symptoms
Treatment implication
Responds less well to peripherally directed care (anti-inflammatories, opioids, surgery, injections); better suited to education, graded activity and psychological approaches
Still debated
Whether central sensitization causes chronic pain, or accompanies it (Velasco et al., 2024)

Key takeaways

  • Nociplastic pain is a third mechanism, alongside nociceptive (tissue) and neuropathic (nerve) pain, and the three can mix in the same person.
  • Its practical importance is in what does not work well: treatments aimed at tissues. Recognizing it can end a long search for a structural cause.
  • Central sensitization is a related neurophysiological idea, much of it from animal research, and hard to measure directly in people. The two terms are not interchangeable.
  • Clinical criteria exist (Kosek et al., 2021), and a 2024 consensus describes how to classify low back pain as nociceptive, neuropathic, nociplastic or mixed.
  • Telling someone their pain is nociplastic is never saying it is not real. A useful framing is that the alarm system has become more sensitive, and sensitivity can be turned down.

What does nociplastic pain mean?

In their 2021 review in The Lancet, Mary-Ann Fitzcharles, Daniel Clauw and colleagues described nociplastic pain as a third category that is mechanistically distinct from the other two. Its mechanisms are not fully understood, but augmented pain and sensory processing in the central nervous system, along with altered pain modulation, are thought to play the leading roles.

People with nociplastic pain often report pain in several body regions, pain that is more intense than any visible tissue problem would explain, and other symptoms that seem to come from the central nervous system: fatigue, poor sleep, memory difficulties and mood changes. Nociplastic pain can occur on its own, as in fibromyalgia or tension-type headache, or mixed with nociceptive or neuropathic pain, as often happens in chronic low back pain.

The practical point the authors emphasized is the one that changes treatment. Nociplastic pain tends to respond less well to treatments aimed at the periphery, such as anti-inflammatory drugs, opioids, surgery or injections.

How do clinicians recognize nociplastic pain?

Naming a category is only useful if clinicians can identify it. In 2021, Eva Kosek and colleagues proposed clinical criteria and a grading system for chronic nociplastic pain affecting the musculoskeletal system (Kosek et al., 2021). The criteria weigh the duration and distribution of pain, the absence of a sufficient nociceptive or neuropathic explanation, signs of pain hypersensitivity, and associated symptoms such as sleep problems, fatigue and cognitive complaints.

In 2024, an international consensus group published recommendations specifically for classifying low back pain as nociceptive, neuropathic, nociplastic or mixed (Nijs et al., 2024). This kind of phenotyping is meant to match people with treatments that fit their dominant mechanism, rather than treating every back as if it had the same problem.

Is nociplastic pain the same as central sensitization?

The terms travel together, but they are not the same thing. Central sensitization describes a state in which neurons in the spinal cord and brain become more responsive, so that ordinary input is amplified. Reviews have linked these states to neuroinflammation (Ji et al., 2018) and to changes in brain function and structure, immune processing and peripheral factors (Kaplan et al., 2024). People with nociplastic pain are often diffusely tender and can be more sensitive than others to non-painful stimuli such as light, odors and noise.

It is worth being careful here. Central sensitization is a neurophysiological concept, much of it studied in animals, and it is hard to measure directly in people. A 2024 critical review asked whether chronic pain is in fact caused by central sensitization and urged caution about treating the two terms as interchangeable (Velasco et al., 2024). Even the researchers who championed the nociplastic concept have written about where it needs to go next (Kosek et al., 2024).

Honest communication means acknowledging that the science is still developing. Nociplastic pain is a clinical description of a pattern; central sensitization is one proposed mechanism behind it. The first is observable at the bedside. The second is inferred.

Why does the nociplastic label change treatment?

If pain is being driven largely by changes in how the nervous system processes signals, it makes sense to choose treatments that target the nervous system and the person's relationship with their pain rather than the tissues. The approaches with the best support include:

  • Pain neuroscience education, which helps people understand why their pain persists and reduces threat. Reviews in people with signs of central sensitization have examined this directly (Lepri et al., 2023). See does it work?
  • Graded movement and exercise, which help the nervous system relearn that activity is safe.
  • Psychological approaches such as pain reprocessing therapy, cognitive behavioral therapy and acceptance-based therapies, which address fear, attention and beliefs.
  • Attention to sleep, stress and mood, all of which influence pain processing.

Recognizing nociplastic features can also help clinicians and patients avoid an endless search for a structural cause, or repeated procedures that are unlikely to help. Our guide to chronic pain treatment lays out the options and the evidence behind each.

Does nociplastic mean the pain is not real?

No. Telling someone their pain is central or nociplastic can be heard as "it's not real" or "it's in your head", and that is never the message. Nociplastic pain is real pain produced by a real nervous system. A useful framing for patients is that the alarm system has become more sensitive, and that sensitivity can often be turned down with the right combination of understanding, movement and support.

The concept is still being refined, and its relationship to central sensitization is debated. But it has already changed how clinicians think about treatment, steering care toward approaches that work with the nervous system rather than chasing causes that scans cannot find. Karuna's program is designed for exactly this kind of pain; see how it works.

Frequently asked questions

Is nociplastic pain the same as neuroplastic pain?

Close. Nociplastic pain is the formal IASP term for pain arising from altered nervous system processing without tissue or nerve damage. Neuroplastic pain is a plainer-language name used by some clinicians and by this site for the same idea, with an emphasis on the fact that the processing is learned and can change. Our guide to neuroplastic pain covers it.

Which conditions are considered nociplastic?

Fibromyalgia is the clearest example, along with tension-type headache and several conditions where pain persists without a tissue explanation. Nociplastic mechanisms also mix with nociceptive or neuropathic ones in common conditions such as chronic low back pain, which is why the 2024 consensus on back pain classification exists.

Can nociplastic pain be diagnosed with a test?

No single test confirms it. Diagnosis is clinical, using criteria such as those proposed by Kosek and colleagues: the duration and spread of pain, the absence of a sufficient nociceptive or neuropathic explanation, signs of hypersensitivity, and associated symptoms like fatigue, poor sleep and cognitive difficulty. Normal scans and bloodwork are expected rather than reassuring evidence that nothing is wrong.

Do painkillers work for nociplastic pain?

Less well than for nociceptive pain. The Lancet review notes that nociplastic pain responds poorly to treatments aimed at the periphery, including anti-inflammatory drugs, opioids, surgery and injections. Some medications that act on the nervous system help some people modestly. Never change a medication without talking to whoever prescribed it.

Is central sensitization proven to cause chronic pain?

It is widely proposed, not proven. Much of the underlying research is in animals, and it is hard to measure central sensitization directly in people. A 2024 critical review (Velasco et al.) questioned whether it causes chronic pain or accompanies it. The nociplastic label stands on the clinical pattern, which is observable, rather than on any one mechanism.

Sources & research.

  1. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-2110. PMID 34062144
  2. Kosek E, Clauw D, Nijs J, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021;162(11):2629-2634. PMID 33974577
  3. Nijs J, et al. Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium's international and multidisciplinary consensus recommendations. Lancet Rheumatol. 2024. PMID 38310923
  4. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129(2):343-366. PMID 29462012
  5. Kaplan CM, Kelleher E, Irani A, et al. Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms. Nat Rev Neurol. 2024. PMID 38755449
  6. Velasco E, et al. Is chronic pain caused by central sensitization? A review and critical point of view. Neurosci Biobehav Rev. 2024. PMID 39278607
  7. Kosek E, et al. The concept of nociplastic pain: where to from here? Pain. 2024. PMID 39560415
  8. Lepri B, et al. Effectiveness of pain neuroscience education in patients with chronic musculoskeletal pain and central sensitization: a systematic review. Int J Environ Res Public Health. 2023;20(5):4098. PMID 36901108

Related guides.

Free consultation

Ready to unlearn your pain?

Talk with our care team about your pain, your history, and whether KVET™ is right for you. Free, and from the comfort of home.

Free. No symptom or health details are collected on this form.